Understand KRAS and the Quest for Anti-Cancer Drugs

The KRAS oncogene is mutated in approximately similar to 30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.

Automated summary

The KRAS oncogene is mutated in around 30% of human cancers, making it a key target for cancer research. Direct targeting of KRAS has proven to be ineffective, leading researchers to explore alternative approaches for drug development. This review provides an overview of KRAS structure, signaling pathways, challenges with existing inhibitors, and potential avenues for future drug development.